Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Weighted Average and Diluted): 2018-2024

Historic EPS (Weighted Average and Diluted) for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Dec 2024 value amounting to $1.31.

  • Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) rose 20.00% to $0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.72, marking a year-over-year increase of 45.76%. This contributed to the annual value of $1.31 for FY2024, which is 107.94% up from last year.
  • Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to $1.31 in FY2024, which was up 107.94% from $0.63 recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $1.31 in FY2024 and a low of $0.37 during FY2021.
  • Over the past 3 years, Catalyst Pharmaceuticals' median EPS (Weighted Average and Diluted) value was $0.75 (recorded in 2022), while the average stood at $0.90.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) soared by 136.67% in 2020 and then slumped by 47.89% in 2021.
  • Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at $0.71 in 2020, then crashed by 47.89% to $0.37 in 2021, then soared by 102.70% to $0.75 in 2022, then decreased by 16.00% to $0.63 in 2023, then soared by 107.94% to $1.31 in 2024.